Latest News

• Upcoming webinar: Sonodynamic therapy using focused ultrasound for people with gliomas        

   Mark your calendars for December 18 at 7pm EST! We'll be hosting a webinar with Dr. Michael Schulder on sonodynamic therapy for high-grade gliomas. 

  
  
• Musella Foundation 2024 Highlights        

  As we close out the year, we're proud to share our Musella Foundation 2024 Highlights. Everything we do —funding research, expanding patient navigation services, providing vital educational resources, patient advocacy— can only be done with your support. Please consider making a year-end donation to help us continue driving progress, supporting patients and families, and bringing hope to the brain tumor community. Every dollar helps! 

  
  
• Advocacy Alert! Ensuring Patient Access to Critical Breakthrough Products Act: H.R. 1691 and S. 5349        

  Under our current system, there is a 4.7 year gap between when a medical device gets FDA approval and when it gets coverage by Medicare. This proposed bill would close this "Valley of Death" lag for Medicare beneficiaries. If enacted, this bipartisan legislation will help ensure that American seniors are granted faster access to innovative medical devices and diagnostics. For brain cancer patients, there are at least 3 medical devices in development that may be eligible for this once approved by the FDA. We do not have 4 extra years to wait for Medicare to allow us access to these treatments! To advocate in favor of this bill, please click here!

  
  
• Treatment-related survival patterns in diffuse intrinsic pontine glioma using a historical cohort: A report from the European Society for Pediatric Oncology DIPG/DMG Registry        

  The Musella Foundation helped fund this research looking at how different treatment options affect length of survival for children with DIPG. Children with DIPG who did not receive any treatment had a median survival of just 3 months. Children who had only radiation lived for a median of 10.4 months from diagnosis. Those treated with both radiation and chemotherapy had a median survival of 11.7 months. These numbers are horrific and show that new treatments are urgently and desperately needed. If the Promising Pathway Act was passed, we would have better treatments right now.